Particular challenges for test reproducibility are represented by BC specimens with a low ERα and/or low PgR expression (1–10%), whose assessment could be affected by both pre-analytic (e.g., fixation type and time) and analytic factors (e.g., antibody used), as well as by the tumor heterogeneity of the HR expression [94]. The gene discussed is PGR; the disease is breast cancer.